California is taking aim at high insulin prices with its own drug label, CalRx, with “below-market prices,” the Los Angeles Times reported June 6. If fulfilled, the state will be the first to challenge the pharmaceutical industry.
Read the full post on Becker's Hospital Review - Healthcare News
